Clinical Study to Assess the Effectiveness of Navkarshik Kwath Versus Allopurinol in Treating Gouty Arthritis.

A Controlled clinical study to evaluate the efficacy of navkarshik kwath in vatashonita w.s.t to gouty arthritis - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/073056

Enrollment

Registered

2024-08-28

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease Health Condition 2: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria Age 21 – 60 years Sex Both male & female Socioeconomic status All The patients of Vatashonita having serum uric acid more than 7 mg/dl in males and more than5.7 mg/dl in females and all 3 essential criteria with at least one non essential criteria . Essential Criteria- 1.pain in the affected joint 2.Swelling in the affected joint 3.tenderness in affected area Nonessential Criteria 1.redness in the affected joint 2.Stiffness / decreased / restricted movements of joint 3.Itching in affected joint 4.Burning sensation over joint

Exclusion criteria

Exclusion criteria: Exclusion Criteria of the patient- 1. Patients below 21 years and above 60 years of age. 2. Complicated cases of gouty arthritis by others systemic disorders like uncontrolled Diabetes, Thyroid disorders and Psoriatic arthritis etc. 3. Complicated cases of vatashonita by its updravas like Hikka, Moorchha, Moha, Visarpa, mansa-koth, angulivakrata, etc. 4. Complicated cases of gout with chronic joint deformity, marked dysfunction, discharging tophi etc. 5. Pregnancy and lactation. 6. Patients with rheumatoid Arthritis, Osteo Arthritis, SLE, , Tuberculosis, Renal disease, Hepatic disease.

Design outcomes

Primary

Measure	Time frame
All the signs & symptoms are graded 0, 1, 2, 3 or 0, +, ++,+++ (nil, mild, moderate & severe) on the basis of its intensity & severity given by patients on complained & confirmed by clinical examination before the trial drugs. The clinical improvement during and after trial drugs will also be correlated with previous intensity of the signs & symptoms.Timepoint: at every 15 days interval after first guest visit on day zero. We would also like to meet with you one month after completion of treatment (day 90) for a final check-up.	—

Measure

Time frame

All the signs & symptoms are graded 0, 1, 2, 3 or 0, +, ++,+++ (nil, mild, moderate & severe) on the basis of its intensity & severity given by patients on complained & confirmed by clinical examination before the trial drugs. The clinical improvement during and after trial drugs will also be correlated with previous intensity of the signs & symptoms.Timepoint: at every 15 days interval after first guest visit on day zero. We would also like to meet with you one month after completion of treatment (day 90) for a final check-up.

—

Secondary

Measure	Time frame
The quantitative analysis of the values of the serum uric acid will be done before & after the treatment and during the follow up to compare the inflammatory condition of the affected joints.Timepoint: at every 15 days interval after first guest visit on day zero. We would also like to meet with you one month after completion of treatment (day 90) for a final check-up.	—

Countries

India

Contacts

Public ContactDr Shachi srivastava

State ayurvedic college & hospital turiyaganj tulasidas marg lucknow.

drmanojkumar2018ydv@gmail.com8004592624

Outcome results